ZNTL NASDAQ
Zentalis Pharmaceuticals, Inc.
1W: -14.6%
1M: -18.2%
3M: -0.3%
YTD: +156.2%
1Y: +140.4%
3Y: -86.1%
5Y: -94.8%
$3.51
-0.08 (-2.23%)
Weekly Expected Move ±10.4%
$3
$3
$4
$4
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$15.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$249.9M
52W Range1.212-6.95
Volume787,720
Avg Volume1,126,317
Beta1.86
Dividend—
Analyst Ratings
Company Info
CEOJulia Marie Eastland
Employees106
SectorHealthcare
IndustryBiotechnology
IPO Date2020-04-03
Websitezentalis.com
10275 Science Center Drive
San Diego, CA 92121
US
San Diego, CA 92121
US
212 433 3791
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Latest News
BlackRock Inc. Invests $18.20 Million in Zentalis Pharmaceuticals, Inc. $ZNTL
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| WALTERS GROUP | P-Purchase | 4,335,000 | $3.50 | 2026-08-14 |
| Johnson David Michae | A-Award | 57,100 | — | 2026-06-16 |
| Skvarka Jan | A-Award | 57,100 | — | 2026-06-16 |
| Walker Luke Nathanie | A-Award | 57,100 | — | 2026-06-16 |
| Kariuki Enoch | A-Award | 57,100 | — | 2026-06-16 |